Search the Newsreel

Phio's PH-894 Patent Allowance Spans Proliferative and Infectious Diseases

Phio Pharmaceuticals announced a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL-based compound designed to selectively silence the BRD4 protein, which is linked to proliferative and infectious diseases. This patent strengthens the company's intellectual property portfolio, now comprising 54 issued patents …

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Phio Pharmaceuticals has received a U.S. Notice of Allowance for a patent covering PH-894, a compound designed to selectively silence the BRD4 protein, which is linked to proliferative and infectious diseases. This strengthens the company's intellectual property for its INTASYL® gene-silencing technology and supports …

Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Phio Pharmaceuticals Corp (PHIO) has an earnings forecast score of 8.00, placing it 171st out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $14.00 for PHIO, with a strong buy recommendation based on the rating …

PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs

Phio Pharmaceuticals (PHIO) is advancing its PH-762 clinical program with ongoing key studies and preparations for FDA submission. The company's financial position is projected to support operations until late 2027, despite an increase in R&D expenses and a higher net loss compared to the …

Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary

Phio Pharmaceuticals Corp. reported a net loss of $(4.14)M and diluted EPS of $(0.36) for Q2 2026, remaining pre-revenue. Key highlights include the completion of PH-762 Phase 1b trial enrollment with promising results in cSCC, initiation of cGMP drug substance manufacturing, and a planned …

Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program

Phio Pharmaceuticals reported a net loss of $4.1 million for Q2 2026, with $13.0 million in cash and cash equivalents, expected to fund operations into the second half of 2027. The company is advancing its lead INTASYL candidate, PH-762, having completed a Phase 1b …

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals Corp. reported its second-quarter 2026 financial results, highlighting significant progress in its PH-762 development program, including the initiation of commercial scale API production and a long-term non-clinical toxicology study. The company completed its Phase 1b clinical trial for PH-762 and plans to …

Phio intends to request an FDA meeting after 22-patient cancer study

Phio Pharmaceuticals reported its Q2 2026 financial results, including a net loss of $4.1 million and cash and equivalents of $13.0 million, which is expected to fund operations into the second half of 2027. The company completed a 22-patient Phase 1b trial for its …

Phio Pharmaceuticals (PHIO) Earnings Date and Reports 2026

Phio Pharmaceuticals director Ronald Todd Plott files initial beneficial ownership statement

Phio Pharmaceuticals has announced that Ronald Todd Plott was named a director on July 20, 2026. This information was filed via a Form 3. The news brief was generated by Public Technologies using AI based on content from the U.S. SEC's EDGAR system.

Phio Pharmaceuticals Corp (PHIO) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Phio Pharmaceuticals Corp (PHIO), noting its current valuation score of 7.99, which ranks 174 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -0.71, indicating it is significantly below …

Phio Pharmaceuticals Corp (PHIO) Institutional Confidence

This article from TradingKey provides an overview of Phio Pharmaceuticals Corp's institutional confidence. It details the institutional shareholding and shareholder activity for PHIO, listing several firms and individuals along with their shares held and percentage change. The institutional confidence score was 3.00 as of …

Phio Pharmaceuticals Corp (PHIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Phio Pharmaceuticals Corp (PHIO), listing major individual and institutional holders and their respective proportions. It also presents historical institutional shareholding data and recent shareholder activity, including changes in holdings by key investors.

Phio Pharmaceuticals Corp (PHIO) Balance Sheet

This page provides a detailed balance sheet for Phio Pharmaceuticals Corp (PHIO), offering both quarterly and annual data for evaluating the company's financial health. It includes key financial metrics such as cash and short-term investments, total assets, current assets, liabilities, and shareholders' equity, along …

Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Phio Pharmaceuticals Corp (PHIO), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. PHIO currently has a price momentum score of 4.96, ranking 142nd in its industry, trading between a resistance …

Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO

This article provides a link to Phio Pharmaceuticals Corp.'s (NASDAQ: PHIO) revenue breakdown on TradingView. It indicates that the market was closed at the time of viewing and offers various financial and analytical tools for the company. The page also includes general information about …

PHIO|Phio Pharmaceuticals Corp|Price:1.010|

Phio Pharmaceuticals Corp (PHIO) is a clinical-stage biotechnology company focused on developing therapeutics for cancer treatment using its INTASYL self-delivering RNAi technology. The company's pipeline includes PH-762 and PH-894, targeting PD-1 and BRD4 respectively, to enhance the immune system's ability to fight tumors. The …

PHIO|Phio Pharmaceuticals Corp|Price:1.075|Chg%:+0.015

Phio Pharmaceuticals Corp (PHIO) exhibits relatively healthy fundamentals and high growth potential, though its valuation is considered fair within the Biotechnology & Medical Research industry. Despite a positive stock market performance and strong fundamentals recently, technical analysis suggests a possible downward trend in the …

Phio Pharmaceuticals to present its INTASYL siR...

Phio Pharmaceuticals will present its INTASYL siRNA gene silencing technology and lead cancer drug PH-762 on July 28, 2026, during a virtual non-deal roadshow. CEO Robert Bitterman will discuss PH-762, which is designed to silence the PD-1 gene to enhance the immune response against …

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Corp. has issued a correction regarding its participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series. The company's CEO, Robert Bitterman, will present an overview of their INTASYL® siRNA platform, including the lead clinical candidate PH-762 for cutaneous carcinomas, followed …

Phio Pharmaceuticals appoints dermatologist to board By Investing.com

Phio Pharmaceuticals Corp. has appointed R. Todd Plott, M.D., a board-certified dermatologist with over 30 years of experience, to its Board of Directors. Plott's expertise in dermatologic care and clinical development will aid the company in advancing its PH-762 therapeutic for squamous cell carcinoma, …

Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee

Phio Pharmaceuticals has announced the appointment of R. Todd Plott, M.D., to its Board of Directors, effective July 20, 2026. Dr. Plott will also serve as a member of the Governance Committee. He brings over 30 years of experience in dermatologic care and innovation, …

More Than 30 Years in Dermatology: Phio Adds a Director

Phio Pharmaceuticals has appointed Dr. R. Todd Plott, a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, to its Board of Directors. Dr. Plott's extensive background in dermatologic care, clinical research, drug development, and overseeing hundreds of clinical …

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Phio Pharmaceuticals has appointed Dr. R. Todd Plott, an experienced dermatologist and researcher, to its Board of Directors. Dr. Plott brings over 30 years of experience in dermatologic care, clinical development, and as a former FDA advisory committee member, which will be a valuable …

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Phio Pharmaceuticals Corp. announced significant progress in protecting its proprietary INTASYL® gene silencing technology, securing multiple favorable patent actions including three notices of allowance and one grant decision in the United States, Canada, and Japan. This strengthens the company's global intellectual property portfolio for …

Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan

Phio Pharmaceuticals (NASDAQ:PHIO) announced patent allowances and a grant decision in the U.S., Canada, and Japan for its INTASYL compounds, strengthening its intellectual property portfolio to 54 issued patents. The company's CEO emphasized the importance of strong patent protection for advancing immuno-oncology therapies. Despite …

Phio Pharmaceuticals: 3 Patent Allowances, 1 Grant | PHIO Stock News

Phio Pharmaceuticals (NASDAQ: PHIO) has announced significant progress in expanding its intellectual property for its INTASYL® gene silencing technology, receiving three patent notices of allowance and one grant decision across the United States, Canada, and Japan. These new patent actions enhance the company's global …

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Phio Pharmaceuticals has expanded its global intellectual property protection for its INTASYL® gene silencing platform with new patent milestones in the United States, Canada, and Japan. These additions bring the company's patent portfolio to 54 issued patents, covering various aspects of its technology, including …